• Pila Pharma posted an H1 2026 update covering its interim report review and related management interviews, centered on recent clinical progress.
• Materials include discussions of regulatory clearance for a longer obesity trial using its oral TRPV1 antagonist.
• Web links were provided to video postings on YouTube and other sites, including https://www.youtube.com/watch?v=FjVmquk8zq0.
• The release flagged more events may be announced on its website at https://www.pilapharma.com/.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.